LifeTime and improving European healthcare through cell-based interceptive medicine
Author(s)
Type
Journal Article
Abstract
Here we describe the LifeTime Initiative, which aims to track, understand and target human cells during the onset and progression of complex diseases, and to analyse their response to therapy at single-cell resolution. This mission will be implemented through the development, integration and application of single-cell multi-omics and imaging, artificial intelligence and patient-derived experimental disease models during the progression from health to disease. The analysis of large molecular and clinical datasets will identify molecular mechanisms, create predictive computational models of disease progression, and reveal new drug targets and therapies. The timely detection and interception of disease embedded in an ethical and patient-centred vision will be achieved through interactions across academia, hospitals, patient associations, health data management systems and industry. The application of this strategy to key medical challenges in cancer, neurological and neuropsychiatric disorders, and infectious, chronic inflammatory and cardiovascular diseases at the single-cell level will usher in cell-based interceptive medicine in Europe over the next decade.
Date Issued
2020-11-01
Date Acceptance
2020-08-25
Citation
Nature, 2020, 587 (7834), pp.377-386
Start Page
377
End Page
386
Journal / Book Title
Nature
Volume
587
Issue
7834
Copyright Statement
© The Author(s) 202. This article is licensed under a Creative Commons Attribution
4.0 International License, which permits use, sharing, adaptation, distribution
and reproduction in any medium or format, as long as you give appropriate
credit to the original author(s) and the source, provide a link to the Creative Commons license,
and indicate if changes were made. The images or other third party material in this article are
included in the article’s Creative Commons license, unless indicated otherwise in a credit line
to the material. If material is not included in the article’s Creative Commons license and your
intended use is not permitted by statutory regulation or exceeds the permitted use, you will
need to obtain permission directly from the copyright holder. To view a copy of this license,
visit http://creativecommons.org/licenses/by/4.0/.
4.0 International License, which permits use, sharing, adaptation, distribution
and reproduction in any medium or format, as long as you give appropriate
credit to the original author(s) and the source, provide a link to the Creative Commons license,
and indicate if changes were made. The images or other third party material in this article are
included in the article’s Creative Commons license, unless indicated otherwise in a credit line
to the material. If material is not included in the article’s Creative Commons license and your
intended use is not permitted by statutory regulation or exceeds the permitted use, you will
need to obtain permission directly from the copyright holder. To view a copy of this license,
visit http://creativecommons.org/licenses/by/4.0/.
License URL
Sponsor
Medical Research Council (MRC)
UK DRI Ltd
UK DRI Ltd
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/32894860
PII: 10.1038/s41586-020-2715-9
Grant Number
HQR00720
N/A
N/A
Subjects
Artificial Intelligence
Cell- and Tissue-Based Therapy
Delivery of Health Care
Early Diagnosis
Education, Medical
Europe
Female
Health
Humans
Legislation, Medical
Male
Medicine
Pathology
Single-Cell Analysis
Publication Status
Published
Coverage Spatial
England
Date Publish Online
2020-09-07